Fig. 5: The cross-neutralization capacity of RM sera elicited by RBD-homodimer on SARS-CoV-2 variants. | Cell Discovery

Fig. 5: The cross-neutralization capacity of RM sera elicited by RBD-homodimer on SARS-CoV-2 variants.

From: RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates

Fig. 5: The cross-neutralization capacity of RM sera elicited by RBD-homodimer on SARS-CoV-2 variants.The alternative text for this image may have been generated using AI.

a The OD450 of four RM sera (1:400 diluted) elicited by WT RBD dimer was detected on nine eukaryotic RBD variants and one WT RBD with conventional ELISA. b Sera adopted from four vaccinated RMs were detected by hACE2-RBD blocking assays. The mutants were presented, and the inhibition% was equal to blocking rate. c The neutralizing antibody titers calculated from b were displayed (unpaired t-test with WT). d The neutralizing antibody titer of twenty RM sera vaccinated with RBD dimer against both WT and 501Y.V2 were detected by PRNT (paired t-test). ns, P > 0.05, *P < 0.05, **P < 0.01.

Back to article page